(Q27851478)

English

Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma.

scientific article

Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

2 references

PubMed publication ID

13 November 2016

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19648970%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19648970%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

transplantation

0 references

phase I clinical trial

0 references

1 reference

based on heuristic

inferred from title

Angela Dispenzieri

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19648970%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Scott H Kaufmann

22

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19648970%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1

object named as

M R Litzow

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19648970%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

9

object named as

M A Gertz

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19648970%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

11

object named as

M Q Lacy

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19648970%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

19

object named as

V J Suman

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19648970%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Stephanie L Safgren

3

object named as

S L Safgren

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19648970%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

14

object named as

W L Lingle

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19648970%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Marlene H Frost

16

object named as

M H Frost

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19648970%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Lynn C. Hartmann

15

object named as

L C Hartmann

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19648970%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

author name string

P P Peethambaram

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19648970%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

G L Keeney

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19648970%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

S M Ansell

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19648970%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

M A Elliott

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19648970%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

D A Gastineau

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19648970%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

D J Inwards

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19648970%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

I N M Micallef

12

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19648970%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

L F Porrata

13

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19648970%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

B A Barrette

17

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19648970%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

H J Long

18

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19648970%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

J M Reid

20

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19648970%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

M M Ames

21

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19648970%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

language of work or name

0 references

publication date

3 August 2009

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19648970%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Bone Marrow Transplantation

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19648970%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

45

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19648970%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19648970%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

490-497

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19648970%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Cancer statistics, 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2836387

20 March 2017

Serial intense chemotherapy combining topotecan, etoposide, carboplatin and cyclophosphamide (TECC) followed by autologous hematopoietic stem cell support in patients with high risk soft tissue sarcoma (STS).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2836387

29 September 2017

Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2836387

29 September 2017

Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2836387

29 September 2017

Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2836387

29 September 2017

Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer: a gynecologic oncology group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2836387

29 September 2017

Tumor cell death induced by topoisomerase-targeting drugs.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2836387

29 September 2017

Topoisomerase I-mediated cytotoxicity of N-methyl-N'-nitro-N-nitrosoguanidine: trapping of topoisomerase I by the O6-methylguanine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2836387

29 September 2017

Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2836387

29 September 2017

Efficacy and hematologic toxicity of salvage chemotherapy following stem cell-supported high-dose chemotherapy in women with recurrent ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2836387

29 September 2017

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2836387

29 September 2017

Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2836387

29 September 2017

Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2836387

29 September 2017

Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2836387

29 September 2017

Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2836387

29 September 2017

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2836387

29 September 2017

Phase I study of high-dose topotecan with haematopoietic stem cell support in the treatment of ovarian carcinomas: the ITOV 01 protocol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2836387

2 June 2018

Using yeast to understand drugs that target topoisomerases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2836387

2 June 2018

Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2836387

2 June 2018

High-dose chemotherapy and autologous stem-cell transplantation for ovarian cancer: an autologous blood and marrow transplant registry report.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.181

21 January 2018

Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.181

21 January 2018

High-dose chemotherapy with autologous haemopoietic support for advanced ovarian cancer in first complete remission: retrospective analysis from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT).

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.181

21 January 2018

Phase I topotecan preparative regimen for high-risk neuroblastoma, high-grade glioma, and refractory/recurrent pediatric solid tumors.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.181

21 January 2018

Phase I/II study of tandem cycles of high-dose chemotherapy followed by autologous hematopoietic stem cell support in women with advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.181

21 January 2018

High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.181

21 January 2018

High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.181

21 January 2018

Topotecan in the first-line treatment of small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.181

21 January 2018

Risk factors for adult soft tissue sarcoma in northern Italy

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.181

21 January 2018

Antiproliferative activity of the topoisomerase I inhibitors topotecan and camptothecin, on sub- and postconfluent tumor cell cultures.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.181

21 January 2018

Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.181

21 January 2018

RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.181

21 January 2018

Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2836387

27 November 2018

High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2836387

27 November 2018

A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19648970

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://pubmed.ncbi.nlm.nih.gov/19648970

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gene expression of DNA topoisomerases I, II alpha and II beta and response to cisplatin-based chemotherapy in advanced ovarian carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19648970

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19648970

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19648970

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT

1 reference

https://pubmed.ncbi.nlm.nih.gov/19648970

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BMT.2009.181

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19648970%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Dimensions Publication ID

0 references

PMC publication ID

2 references

PubMed publication ID

13 November 2016

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19648970%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

PubMed publication ID

2 references

PubMed publication ID

13 November 2016

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19648970%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27851478&oldid=2175350260"